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Abstract
Four cases of CBZ-induced or exacerbated hyponatremia are described in middle-aged to
elderly .females. Two cases are remarkable in that the pretreatment sodium levels demonstrate
hyponatremia. A return to prior sodium levels was observed upon the discontinuation ofcarbam-
azepine therapy . No definitioe conclusions can be drawn from these case reports; however,
similarities in the cases can be examined asfoiloios: (1) allfo ur women have medical problems, in
particular two patients had pre-existing hyponatremia; (2) allfo ur patients were using concurren t
medications; (3) all fo ur women presented psychotic. A literature review examines riskf actors,
pharmacological mechanism, and the time coursefor CBZ-inducedhyponatremia.
Carba mazepine-an iminodiben zyl com pound-was introduced int o clinica l
medi cin e in 1962 ( I). Since th at t ime, clinica l stud ies have demonstrat ed ca rbam-
az epine (CBZ) to be effec tive in th e treatment of numerou s psychiatric and neu ro-
logic di sorders such as bip olar di sorder (2,3), unipolar depression (3) , gen era lized
and psychomotor seizures (4,5) , schizophre nia (6), schizoaffec t ive d isorder (6) , pain
syndromes (5,7) , and borderline personality di sorder (8). Addition ally, in 1966
Braunhofer a nd Zicka reported th e an t idiu re tic effect of (C BZ) in neurohypophysial
di ab et es insipidus (9). Unfortunat ely, t he a n t id iu re tic effect of C BZ ca n signifi cantly
com plica te th e effec t ivene ss of C BZ for th e treatment of psychiatric disorder s by
producin g hypon atrem ia. Numerous case re po rts (10-22), studi es (23- 32), an d two
reviews (33,34) have clearly documented th e pr obl e m; however, litt le conse nsus
prevail s towards underst anding either th e mech an ism or pr edisposing ca uses for
CBZ-induced hyponatremia.
In this study, we pr esent four women , middle to elde rly in ag e, who dem on-
st ra te d hyponatremia after a short duration of C BZ th erapy. Of sig nificance is th e
fact that a ll four wom en had pr eviou s medi cal com plica t ions, a nd fu rt hermore, two
were hyponatremic prior to CBZ th erap y. Thus, medi cal com plica tions, espec ia lly a
prior abnor mality of osmoregula t ion were obse rved to be associa ted with hypon atre-
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mia seconda ry to C BZ th erapy in th ese case reports. However, du e to th e sma ll
number of patients a nd th e un controlled nature of this stud y, we are not sug ges ting
th at medi cal com plica t ions, es pec ia lly in osmo regulat ion, represent a stat istica lly
sig nifica nt associat ion with C BZ-induce d hypon at re mia .
CASE REP ORTS
Case J
Mrs. A, a 68 year old wom an with a diagnosis of major depression with psych ot ic fea tures,
was ad m itted to the inpa ti ent psychi atry un it a t th e Universit y Hospi ta l with a 5 day hist ory of
det eriorat ing symptoms wh ich included: depress ed mo od , socia l withdrawa l, insom nia, poor
appe t ite, feelings of guilt a nd hopelessness, mood cong ruent aud itory hallucinat ions, and
religious delusions. The patient had been a nursing home resident for 13 years a nd had a long
history of re current major depression wit h psychotic features and chronic medi cal problems.
On ad m ission , the pat ient was rec eiving th e following m edications: ph enobarbital (30 mg each
morning a nd 60 mg at nigh t), t razod on e 200 mg at nigh t tim e, di azepam 5 mg three tim es
dai ly a nd NPH insulin 12 units eve ry morning. Admitting labs were as follows: se rum sodi um
131 meq / I, (hyponat re rnic): serum chloride 98 meq /I , se ru m potassium 4.5 me q / I, serum CO2
28 meq / l, blood ur ea nitrogen 6 mg/d l, se ru m crea t inine 0.6 mg/dl , se ru m glucose 102 mg /dl,
and ph enobarbital level 25 mg/1. Liver fun ction tests, hem at ologic, a nd th yroid studies were
normal. A head CT scan revea led som e ce re bra l a nd cereb ellar at rophy as well as an old infarct
in th e left frontopari eta l lobe. An EEG showed diffuse symmetric and excessive fast act ivity,
but no epilept ifor m foci.
Ph enoba rbital was tapered slowly, and th en C EZ was sta rted to tr eat both th e seizure
disorder and th e affective illn ess , a nd tit rat ed to a dos age of 600 mg per day. The patient was
medically st abl e during th e cha nge -over peri od and was th erap eutic on C EZ after several days
(leve l of 7 mg/ I). Sin ce th e pat ient was st ill com pla ining of a ud ito ry hallucin ations, haloperid ol
2 mg three times daily was adde d to th e regim en . One week la ter , thi s pati en t was in an ac ut e
confusional st at e, ori ented on ly to person, drowsy, incontinent of urine, had slurred speech ,
and could no longer rem ember the names of staff member s. Laboratory studies revea led th at
t he pa tient's serum sodium level had dropped significa nt ly to 119 meq /1. All rem aini ng
lab oratory stud ies were unremarkable including th e CEZ level (7 mg/ I). The se rum os mo la lity
on th e following day was 247 mOsm /kg (normal = 275-295 i\Iosm /kg) and uri ne osmolality
measured 2 days lat er was 255 Mosm /kg with a urine sodium of 68 me q / 1. The CEZ was
discontinued and th e patient was fluid restrict ed . Du e to th e patient 's past hist ory of a seizure
disorder, th e patient was sta rted on ph en ytoin which was t itrat ed up to a dose of200 mg twice
dai ly. The delirium cleared to her pr eviou s baselin e menta l sta t us two days afte r sto pping the
CEZ, a nd th e serum sod ium gradually increased to 133 meq / I over th e next week .
Case II
.'vII'S. E, a n 80 yea r old wom en , with an approximate 60-year histo ry of bipolar disorder,
pr esented to th e e me rge ncy room expe riencing a relapse of her primary a ffect ive disorder. On
pr es entation, th e patient described a I week history of a hypom ani c e pisode cons ist ing of th e
following symptoms: m idd le insomnia, eleva te d mood, grandiose ideation, incr eased energy,
and incr eased sexua l pr eoccupation . In add it ion, sh e described drinki ng a pproximately I
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a lcoho lic drink per day. Prior to admission the patient's m edi cations included : lovast at in 1 mg
twice da ily, a nd t riavil 2- 10 (2 mg perphenazine and 10 mg amitriptylin e) on e tabl e t in t he
morning a nd two tablet s at night.
On adm ission the patient's manic episode was cont rolled with low doses of bot h ha lop eri-
dol a nd lorazep am. Ad m ission lab s revealed the following: sodium of 134 meq / I (hypon a-
tremic) , potassium 01'4.5 meq / I, chlor ide 99 meq / I, CO2 27 meq /I , glucose 104 mg/d l, crea ti ne
0.7 mg /dl a nd blood ur ea nitrogen II mg/dl , normal liver fun cti on test s, norm al thyroid and
hematology studies. C BZ treatment was initiat ed and titrat ed to 200 mg twice daily; however,
t hree days a ft er ini t iating C BZ, the pati ent t r ipped and suffe red a mild contusion of her left
for eh ead. Laboratory a nd radiologic st udies were orde re d with th e followin g result s: sod ium
125 rneq / I, pot assium 4.8 m eq /I , chlo ride 9 1 meq /I , CO2 26 meq /I , a nd a norm a l head CT
sca n. Att empts were made to continue the C BZ t reatment whi le man aging this ac u te
exacerba t ion of the hyponatremia with fluid restriction, 1500 ml /day. The pat ient 's sod iu m
level fluctu ated between 122 and 13 1 m eq /I with serum os mo la lity of 265 mOsm / l, req uir ing
the discontinuation ofCBZ II days a fte r init iation . Over the next 2 week s the pa ti ent 's sod ium
levels followed an upward tr en d and a t dis charge, th e level was 133 meq /] .
Case III
Mrs. C , a 54 year old mentall y re tard ed fem al e, with a lon g hist ory of ch ro nic undi ffe ren-
t ia ted schizophre nia requiring numerous hospitali zation s, was transferred from a sma ll
com m unity hospit a l to th e Un ivers ity Ho spit al. T he schizo phre n ia had been man aged effec-
tivel y wit h an t ipsyc hotic medication ; however, du e to th e fact that th e patient 's pr ior
sym pto ms sugges te d a neuroleptic mali gn ant synd ro me (e leva te d temperat u re of 100° F a nd
crea tine kinase of 343 U/ I) th e ph ysicians a t th e com m unity hospit al felt unco mfort ab le
managing the patient with neuroleptics . H er m edi cation s on tr an sfer were as follows:
thioridazine 25 mg twice dail y, clona ze pa rn I mg twice dail y, a lprazola m 0.25 mg three t imes
dai ly, dicloxacillin sod ium 500 mg four tim es daily, g lipizid e 25 mg dail y, sod iu m docusa te 200
mg dai ly, and iron su lfa te 325 mg twice daily.
On pr esent ation t he patient was highly agita te d, required four poin t rest ra in ts, and
remained acutely psych otic. The patient was initiall y managed with lorazepa m, I mg thre e
tim es dai ly, g lyburide 2.5 mg dail y, iron sulfat e 325 mg twice dail y, a nd docusat e 100 mg twice
dai ly. Admission labora tory valu es were as follows: g lucose 124 mg/dl , urea nitrogen II mg/d l,
crea tinine 1.0 mg/dl , sodium 142 me q /I , pot assiu m 4.4 meq /I , ch lor ide 105 meq / I, CO2 27
meq /I , ioni zed ca lciu m 1.37 mm ole /I (sligh t ly eleva ted) . The liver functi on test s, th yro id
fun ction , a nd hematologic laborat ory st udi es were all within th e normal ran ge. A neurologica l
work up revea led a norm al EEG a nd head CT sca n. One week followin g th e neu ro logical
evalua t ion, the patient expe rienced two generalized tonic clon ic se izu res ea ch under 60
seconds . A more in depth neurological eva lua t ion was ini ti at ed ; however, again a ll result s wer e
no rmal. C BZ was start ed an d th e doses were incr eased slowly over a fou r week period until a
th erapeutic level of 8.0 mg/I was obtaine d . Approximat ely two weeks a fte r reach ing a
therap eutic level , a sod ium of 127 meq /I was noted. The pa ti ent com pla ine d of being light
head ed and having difficulty ambu lating. During this period of hypon at remia, urine os mo la lity
was 447 mOsm / kg and se ru m os mola lity was 267 mOsm /kg (no r ma l range 275-295) .
Ph e nytoin was subs t itu ted for C BZ a nd within one week the pa t ient 's sod iu m normal ized .
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Mrs. D, a 58 yea r old whit e fem ale , with an a pproxima te ly 20-year hist ory of a schizoaffec-
tive disorder was ad m itted to th e U nivers ity Hospit al a fter a n acu te exacerbation of her
psych oti c illn ess. The patient 's schizoaffect ive di sorder had been managed with low dose
neu rol eptics, fluph en azin e 5-10 mg per day a nd lithiu m carbona te . Six months prior to th e
ad m ission, she describ ed a progressive return of typical symptoms: isola tion, pers ecutory
de lusion s, messages from th e television , delusion s of referen ce, poor conce nt ration, insomnia,
poor appetit e, low mood , le thargy, a nd sui cid a l ideat ion . On pr esentat ion the pati ent was
irritable, anxious, a nd gua rde d . The admission labora tory evalua t ion; sod ium 143 meq /I ,
glucose 117 mg/dl , pot assium 4.4 meq /I , chlor ide 116 meq /I, CO 2 22 meq / I, liver function
test s, th yroid stud ies, a nd hem at ology stud ies; was normal.
She was ini ti all y man aged with fluph en azin e 5.0 mg twice da ily and th en swit ched to
molindon e 20 mg twice dail y, ben ztropi ne 1.0 mg on an as needed basis, and lorazepam 1.0 mg
on a n as need ed basi s. Du e to th e refract ory nature of Mrs. C's th ou ght disorder, CBZ was
adde d a nd increased to 200 mg three times daily. Rout ine lab or at or y stu d ies were order ed 5
days afte r having reach ed a C BZ do se 01'200 mg three times daily, and were sign ificant for a
sodium of 122 meq /I , crea t inine 0.8 mg/dl, pot assium 4.5 meq /I , chloride 90 meq /l and CO2 24
meq/1. The C BZ was discontinued seco ndary to th e hypon atremi a a nd after I week th e
patient 's hypon atremia resolved .
DI SC USSION
In th is paper, we report 4 case s of C Bl-associated hyponatremia in four
middle-aged to elde rly females, a ll who have medi ca l com plica tions. Two cas es are
remarkab le in th at th e pr etreatment sod ium levels demonstrate hypon a t remia ;
however, even th ese low sodium leve ls were significan t ly decr eased by CBl. Due to
th e fact th at th ese a re isolated reports, few definitive conclusio ns can be made,
althou gh sim ila r ities in th ese cases should be examine d. First, a ll pa tients are
midd le-aged to elde rly females. Second, a ll four women have medi cal problems;
furthermore, two have abnormal osmoreg ulation as defin ed by pr e-exi sting hypon a-
trem ia . Third, all patients were using concurre n t medi cation s, espec ia lly an tipsy-
cho tic medi cations , and a ll pr esented with psych oti c sym pto ms. These case st udies
highlight th e fact that C Bl -ind uced hypon atremia represent s a serious sid e effect
whi ch may not be as rare as pr eviou sly th ou ght.
Nu me ro us cases, mo stly associa ted with neurological di sorders, describi ng CBl-
induced hyponatremia have been reported in th e literature over th e past 20 years
(10-22). Again no conclusions ca n be drawn du e to th e small sa m ple size; however,
some ge ne ra liza t ions ca n be described. First , mo st patients appear to be over 40 years
old; althou gh a case rep ort by Palladino ( 15) describes a 20 yea r old male with
hyponatremia . Second, a ll patients a re suffering from a ne uro logical/psychiatric
di sease. Third, many of th e patients a re tak ing ot her medi cation s in conjunction with
CBl . Fourth, th e time period required for th e onse t of hyponatremia followin g
initiation of CBl th erapy is difficult to asce rt a in, as man y of th e case rep ort s deal
with long term administration of CBl. Fifth, recovery fro m hypon at remia occurs
following withd ra wa l ofCBl. In sum mary, th e pool ed qu an tit ative da ta from the case
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reports a re as follow s: ran ge of age was from 20 to 80 yea rs, ra ng e of C Bl per day was
between 400-1200 mg, a nd levels ran ged from 4.4 to 15 micr ogra ms per lit er.
Even in larger clinica l studies (23-32) , few definiti ve conclusions ca n be mad e
conce rn ing CBl-induced hypon a tremia , since th e dat a among studies a re ofte n
con t radicto ry. Again for th e same reason cite d above minimal da ta exists on the time
course of CBl-induced hypon atremia . The overall incid en ce ra te of CBl-induced
hyponatremia is d ifficult to ascerta in, since the study populat ions from th e man y
a r t icles a re not homogen eou s. Thus, th e dat a ca n not be summ ed , and a range of
0- 33% for th e incid ence rates of CBl-induced hypon atremia is th e onl y descriptive
st ati sti c whi ch ca n be report ed .
The sym pto ms of hyponatremia or water intoxicat ion when plasma sod ium falls
below 120 millieq uivalen t per lit e r (meq / I) inclu de: dizziness, headach e, lethargy,
mental confus ion, mental slowing, weak ness, loss of apa tit e, and hosti lit y. Neu rologi-
ca l ab normalit ies, stupor, convulsions, a nd coma, dom ina te as th e sod ium level fall s
below 110 meq /I (33 ). Mu ch of th e difficulty conce rn ing th e iden t ifica t ion of
CBl-ind uce d hyponatremia involves th e high percentage of asymptomatic individ u-
als with hypon a tremia. In this case report , only hal f the patien ts were sym ptomatic,
a nd in othe r case rep or ts by O 'Ha re e t al. (30) and Kal ff and coworke rs (22) even th e
most seve re ly affected hyponatremic pa tien ts we re asymptom atic. An add it iona l
com plica t ion in th e clinical d iagn osis of CBl-ind uce d hypona t rem ia occurs from th e
overla p of sym pto ms relating to CBl in to xica t ion. In summary, few definitive facts
ca n be asce rtaine d abo ut th e side effect of C Bl -ind uced hypona t rem ia. First , th e
ti me course of C Bl -induced hypona t remia is poo rly defined and may occur afte r
ch ro nic ex pos ure . Second, th e incidence ra te varies from 0-33%. Third, hyponatre-
mia has clearly defin ed sym pto ms; howeve r man y pa t ien ts remain asym pto matic a t
sod iu m levels below 116 meq /1.
An examina t ion of th e C Bl-ind uce d hyponatre mia lite ra ture reveal s numerou s
studies wit h little concurre nce on eithe r ris k factors or me chanism of CBl-induced
hyponatre mia . For exam ple, stu dies by Kal ff a nd coworkers (22) a nd Lahr (23)
identify age as a n important risk fact or; wh ereas num ero us studi es (24-31) do not
demonstrat e a co rre la t ion bet ween age a nd CBl-ind uce d hyponat remia. Simi larl y,
CBl se rum levels have been associa te d with hypona t rem ia in st ud ies by Henry and
coworke rs (27), La hr (23), Ka lff an d colleagues (22) , O 'Hare a nd associat es (30),
while Heli n a nd coworke rs (25) , joffe and associat es (29), and Vieweg a nd coworkers
(32) have not obse rve d a re lat ions hip between CBl serum levels and hypon at remia.
Lastly, on ly Kalff a nd cowo r kers (22) a nd Yassa a nd co lleagues (31) describe a n
associat ion of polyph arm acy a nd C Bl-ind uced hypon a t remia . T hus, even an ex plora -
tion of the previous ly complet ed studies on C Bl-induced hyponatremia fail s to
consistent ly revea l risk facto rs for th e deve lopment ofCBl-induced hypon atremia .
In a similar manne r, th e st udi es exa m ining th e pharmacological mech ani sm s
responsible fo r C Bl-ind uce d hypon atremia fail to elucidate any gen eral conse nsus.
One cou ld specula te on th e mech ani sms of C Bl-induced hypona t remia , i.e ., CBl -
induced hype rse cretion of anti-diuretic hormone (ADH), a direct ac tion of CBl on
renal tu bules, a pos itive syn erg ist ic act ion of CBl and ADH on ren al tu bul es, a
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CBZ-induced decr ea se in osmoreceptor sensit ivit y to sod ium, or lastl y a C BZ-induced
resetting of th e os mo rece pto r thresh old for sod ium . Frah m and colleag ues (35),
Kimu ra a nd associa tes (36), and Ashton a nd cowo r kers ( 10) pr esent evide nce
cons iste n t with a CBZ-induced hypersecr etion of ADH; however, both Frahm and
coa u thors (35) a nd Kimura and colle ag ues (36) use a bioassay, the hydrat ed rat ,
which measures ac t ivity and not conce ntra t ion of ADH. Co nversely, Ka lff and
ass ocia tes (22) , Gold a nd coworke rs (37) , Ste phe ns a nd coa u thors (38) , Meinders a nd
colleagues (39) a nd Thom as a nd associa tes (40) do not support the finding th at CBZ
incr ea ses ADH sec re tion. Furthermor e, th ese studies em ploy radioimmunoassay
(RIA) which a t te m pts to dir ectl y det ermine th e conce n trat ion of ADH , and conse-
qu ent ly, these stud ies con tain a more reliab le assa y for ADH as com pared with a
bioassay. Meinders a nd associa tes (39) conclude in th eir study th at C BZ sensitizes or
ac ts direct ly on th e renal tubules to produce a positive synergis tic effec t with ADH . A
decr ease in os morecep tor se ns itivity to sod ium (the lazy receptor hypothesis) was
cons iste n t with th e dat a from ind ependent st udies don e by both Go ld and coa u thors
(37) a nd St ephens cowor kers (38). In addition, th ese two stud ies proposed that CBZ
may also have a direct effec t on ren al tubular ce lls. Co nve rse ly, T homas and
assoc ia tes (40) deduced fr om th eir data th at CBZ resets th e osmoreceptor threshold
for ADH and docs not affect th e se ns itivity of th e osmoreceptor. T he most probable
mech anism of C BZ-ind uce d hypon atremia involves so me type of C BZ-d irect ed
osmorece ptor perturbation, since th e s tudies implicating this mech anism were more
rigorou s a nd com ple te d with more mod ern assay method ology. However, two of the
s tud ies th at implicat e CBZ-d irec ted osmorecep tor dysfun ction, also reveal concur-
rent evide nce of a C BZ effec t on ren al tubular ce lls. At pr esent the et iology and risk
fact ors associa ted with CBZ-induced hypon at remia remain poorl y defined , and th us ,
furth er stud ies will be need ed to elucida te th e mechanism of CBZ-induced hypona t re-
rma .
Our int erest in this topi c was initially st im ula ted by four in teresting cases .
Althou gh a ll four cases had num erou s fact or s in com mo n; such as female sex , ch ronic
med ical pr ob lems (including pr e-exi st ing hyponat remia) , concurre n t use of medi ca-
tions (es pec ia lly antipsych oti c medi cations) , a nd initial psychoti c presen ta tion; the
lite ra tu re do es not suppor t an y of th ese cha rac ter ist ics as risk fact or for developing
C BZ-ind uce d hypon atremia . Two of th e four pat ients were asymptomatic with
sodiu m levels below 130 meq /l , a n obse rva t ion com mo nly not ed in the lite ra ture.
Conseq uen t ly, e lec trolyte monitoring of patients taking C BZ is necessita ted . In
conclus ion, th e case reports, clini cal stud ies , a nd mech ani sti c stud ies often yield
conflict ing dat a conce rn ing CBZ-induced hyponatremia ; how ever, th e occurren ce of
C BZ-ind uce d hypon atremia is well document ed , a nd thus, physicia ns usi ng CBZ
mu st monitor (bo th clinica lly a nd with elec t ro lyte stud ies) th eir pa tients for thi s
dangerous side effec t.
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